IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Aug 13, 2024 · 10-Q · 44 days after period end · 0001662774-24-000005
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$27.73M | -$4.89M | -$16.56M | -$21.75M |
| EPS Diluted | -$0.64 | -$0.14 | -$0.51 | -$0.74 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end
